Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLRX 
Salarius Pharmaceuticals Inc (SLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: SLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26
1 Year Target Price $26
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.82% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.97M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) 1 | Beta 0.33 | 52 Weeks Range 2.20 - 55.05 | Updated Date 11/7/2025 |
52 Weeks Range 2.20 - 55.05 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -23.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -143.52% | Return on Equity (TTM) -660.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2233487 | Price to Sales(TTM) 18.12 |
Enterprise Value 2233487 | Price to Sales(TTM) 18.12 | ||
Enterprise Value to Revenue 0.14 | Enterprise Value to EBITDA 1.52 | Shares Outstanding 1051782 | Shares Floating 33932 |
Shares Outstanding 1051782 | Shares Floating 33932 | ||
Percent Insiders 0.14 | Percent Institutions 2.51 |
Upturn AI SWOT
Salarius Pharmaceuticals Inc
Company Overview
History and Background
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company founded in 2011. It focuses on developing therapies for cancers that disproportionately affect children, teenagers, and young adults. The company aims to translate epigenetic discoveries into novel treatments.
Core Business Areas
- Drug Development: Development of targeted therapies for cancers, focusing on epigenetic targets such as LSD1.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships and Collaborations: Establishing partnerships with research institutions and other pharmaceutical companies to advance its research and development efforts.
Leadership and Structure
The leadership team typically includes a CEO, CFO, Chief Medical Officer, and other key executives. The organizational structure is that of a typical biopharmaceutical company, with departments dedicated to research and development, clinical trials, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Seclidemstat: Seclidemstat is a reversible LSD1 inhibitor being developed for Ewing sarcoma and other cancers. As a clinical-stage asset, it currently has no direct revenue or market share. Competitors in Ewing Sarcoma development include companies focusing on combination therapies and novel chemotherapies, as well as immunotherapies such as CAR-T cell therapies. Specific competitors include larger pharma companies with more advanced or alternative Ewing Sarcoma treatment pipelines.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and a high failure rate. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in cancer diagnostics and treatment.
Positioning
Salarius is positioned as a company focused on developing targeted therapies for rare cancers. Its competitive advantage lies in its expertise in epigenetic drug development and its focus on underserved patient populations.
Total Addressable Market (TAM)
The TAM for cancer therapies is substantial, estimated to be in the hundreds of billions of dollars. Salarius is targeting niche markets within this larger TAM, specifically rare pediatric cancers. The TAM for Ewing sarcoma is significantly smaller but still represents a valuable market opportunity for targeted therapies.
Upturn SWOT Analysis
Strengths
- Targeted therapy approach
- Focus on rare and underserved cancers
- Experienced management team
- Promising preclinical and clinical data
Weaknesses
- Limited financial resources
- Reliance on a single drug candidate (Seclidemstat)
- High risk of clinical trial failure
- Competition from larger pharmaceutical companies
Opportunities
- Potential for breakthrough therapy designation
- Expansion into other cancer indications
- Strategic partnerships and collaborations
- Increasing awareness of epigenetic targets in cancer
Threats
- Clinical trial failure
- Regulatory hurdles
- Competition from other therapies
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- GILD
- MRK
- BMY
Competitive Landscape
Salarius faces significant competition from larger pharmaceutical companies with greater financial resources and more advanced pipelines. Its competitive advantage lies in its focus on specific epigenetic targets and its expertise in developing therapies for rare cancers.
Growth Trajectory and Initiatives
Historical Growth: Salarius's growth has been primarily driven by the advancement of Seclidemstat through clinical trials and the securing of financing to support these efforts.
Future Projections: Future growth is dependent on the successful completion of clinical trials and the potential approval and commercialization of Seclidemstat or other drug candidates. Analyst estimates vary widely due to the inherent uncertainty in the biopharmaceutical industry.
Recent Initiatives: Recent initiatives may include the initiation of new clinical trials, the announcement of clinical data, and the forging of strategic partnerships.
Summary
Salarius Pharmaceuticals is a high-risk, high-reward clinical-stage biopharmaceutical company focusing on rare cancers. Its success hinges on the progress and approval of Seclidemstat, its primary drug candidate. The company faces financial constraints and competition from larger players, making strategic partnerships crucial for future growth. Investors should closely monitor clinical trial results and regulatory developments.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and is subject to change. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Salarius Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2015-01-29 | Acting CEO, Executive VP of Finance & CFO Mr. Mark J. Rosenblum CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.salariuspharma.com |
Full time employees 2 | Website https://www.salariuspharma.com | ||
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.